Otsuka and Astex announce that the European Commission has approved INAQOVI (oral decitabine and cedazuridine) for the treatment of adults with newly diagnosed acute myeloid leukaemia

Otsuka Pharmaceutical Europe Ltd and Astex Pharmaceuticals Inc on 19 Sep 2023 announce that the European Commission (EC) has approved INAQOVI (oral decitabine and cedazuridine) as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for standard induction chemotherapy. The EC decision applies to the European Economic Area (EEA), which includes the EU member states, Iceland, Liechtenstein and Norway. INAQOVI is the first and only oral hypomethylating agent licensed in the EEA in this patient population. Original source: Otsuka Holdings Co Ltd, website: http://www.otsuka.com/en/, Copyright Otsuka Holdings Co Ltd 2023.
regulations and rulings; anticancer drugs; cedazuridine; decitabine; Astex Pharmaceuticals; Otsuka Pharmaceutical [...]